IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

upadacitinib tablets

upadacitinib extended-release tablets,
for oral use Initial U.S. Approval: 2019

As specified in the prescribing information, upadacitinib tablets is indicated for the treatment of rheumatoid arthritis.  RINVOQis a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. (1) Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.

Facts about upadacitinib tablets

Approval Date: 2019
Proprietary Name: RINVOQ (upadacitinib) extended-release tablets
Active Ingredient(s): upadacitinib
FDA-approved use: rheumatoid arthritis
Dosage Form: Extended-release tablets: 15 mg
Medicine Approved By: US FDA
Manufacturer: AbbVie Inc.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “upadacitinib tablets” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For upadacitinib tablets

Approved accessible "upadacitinib tablets"

Rinvoq (upadacitinib) tablets were originally approved in 2019. In 2022, Rinvoq was approved to treat adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to another type of treatment. Ulcerative colitis is a type of inflammatory bowel disease.

RINVOQis a prescription medicine that is a Janus kinase (JAK) inhibitor. RINVOQ is used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age. Active ingredient: upadacitinib Inactive ingredients: microcrystalline cellulose, hypromellose, mannitol, tartaric acid, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, ferrosoferric oxide, and iron oxide red.

How can 1 go about obtaining upadacitinib tablets?

If upadacitinib extended-release tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

RINVOQ (upadacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2019

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398